PALISADE BIO, INC.
No SEC Form 4 filings for $PALI in the last 30 days.
See all $PALI insider activity →Palisade Bio (PALI) CEO John David Finley gifted 176,800 shares of common stock on August 19, 2026, transferring 88,400 shares to FCW Investments, LLC, which he manages. Post-transaction, he directly holds 129,288 shares and indirectly holds 88,451 shares. The transactions were not under a Rule 10b5-1 trading plan.
PALISADE BIO, INC. (PALI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treat
BlackRock, Inc. filed a Schedule 13G showing beneficial ownership of Palisade Bio, Inc. common stock as of June 30, 2026. BlackRock and its business units report 10,436,760 shares, or 6.0% of the class. It reports sole voting power over 10,326,107 shares and sole dispositive power over 10,436,760 shares.
Over the past 7 days, alphai's AI scored 1 news story mentioning PALI (PALISADE BIO, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PALI coverage spans financial news, insider activity and earnings.
The insider gift disclosure reveals a shift in ownership structure but no immediate cash transaction.
IND clearance plus Phase 2 timing and Phase 1 efficacy highlights increase probability of near-term clinical execution and future readout optionality.
A new 6.0% beneficial ownership disclosure can shift perceived control dynamics and influence near-term positioning around Palisade Bio.
Initiated coverage plus specific clinical and regulatory milestones can support near-term sentiment, but it is not a new trial readout.
Clinical development progress and a planned IND submission are incremental catalysts for PALI, but the article is largely analyst framing rather than new trial readouts.
alphai scores every news story that mentions PALI with an AI model for sentiment and relevance, and aggregates insider trades from PALISADE BIO, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Palisade Bio (PALI) CEO John David Finley gifted 176,800 shares of common stock on August 19, 2026, transferring 88,400 shares to FCW Investments, LLC, which he manages. Post-transaction, he directly holds 129,288 shares and indirectly holds 88,451 shares. The transactions were not under a Rule 10b5-1 trading plan.
1 min readPALISADE BIO, INC. (PALI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treat
7 min readBlackRock, Inc. filed a Schedule 13G showing beneficial ownership of Palisade Bio, Inc. common stock as of June 30, 2026. BlackRock and its business units report 10,436,760 shares, or 6.0% of the class. It reports sole voting power over 10,326,107 shares and sole dispositive power over 10,436,760 shares.
3 min readOppenheimer initiated coverage of Palisade Bio Inc. and said its stock offers exposure to the inflammatory bowel disease market. The company’s lead drug PALI-2108 (PDE4 inhibitor prodrug) showed positive Phase 1a/1b results. The FDA cleared its IND in June for Phase 2 ASCENTRA-UC, with enrollment in 2H 2026 and topline data in 2H 2027. Oppenheimer set a Buy rating and $8 price target.
6 min readBenzinga reports Palisade Bio’s lead drug PALI-2108, a once-daily oral PDE4 inhibitor prodrug, showed positive Phase 1a and 1b results in ulcerative colitis and fibrostenotic Crohn’s disease. The company plans an IND for Phase 2 ASCENTRA-CD in 2H 2026. Analyst Leland Gershell initiated Buy with an $8 price target; Oppenheimer projects peak U.S. sales of $2.6B UC (2040) and $2.8B fibrostenotic CD (2041).
3 min readOppenheimer initiated coverage of Palisade Bio (PALI) with an outperform rating, and the stock rose about 14% in Thursday morning trading. The firm set an $8 price target, implying 321% upside versus the July 22 close. Analyst Lelend Gershell cited potential for PALI-2108.
1 min readBaltera Robert Jr. purchased 45,000 shares of PALISADE BIO, INC. (PALI) at an average of $1.97 ($1.96–$1.99) across 2 trades over 2026-07-08 to 2026-07-09.
1 min readA roundup of July 8, 2026 insider trades reported major buys in Mission Produce (AVO), where Globalharvest Holdings Venture Ltd bought 650,415 shares for about $8.28M at $12.73 avg, and Boundless Bio (BOLD), where Tang Capital bought 57,210 shares for about $141.9K. Major sells included Rocket Lab (RKLB) CEO Peter Beck selling about $286.4M and Dell (DELL) director Egon Durban/Silver Lake selling about $29.9M.
7 min readBaltera Robert Jr. purchased 50,000 shares of PALISADE BIO, INC. (PALI) at an average of $2.04 ($2.03–$2.05, $0.10M total) across 2 trades over 2026-07-06 to 2026-07-07.
1 min readJones Mitchell Lawrence (Chief Medical Officer) sold 51,880 shares of PALISADE BIO, INC. (PALI) at $2.05 ($0.11M total) on 2026-07-07.
1 min read
